Infectious Disease Testing Market Size, Share & Trends Analysis Report By Product & Service (Kits & reagents, Instruments, Software), By Technology (Immunodiagnostics, DNA Sequencing & NGS, PCR), By End User (Hospitals/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Emerging Trends in Infectious Disease Testing Market

Rapid shift toward molecular diagnostics technologies

The infectious disease testing market is undergoing a significant shift toward molecular diagnostic technologies, particularly Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), due to their superior accuracy, sensitivity, and ability to detect pathogens at an early stage. Unlike traditional diagnostic methods, molecular techniques can identify infections even at low viral or bacterial loads, enabling early intervention and improved patient outcomes. PCR remains the gold standard for detecting infectious agents such as viral and bacterial pathogens, while NGS is increasingly used for comprehensive pathogen profiling, including identification of novel or mutated strains.

Integration of ai & digital health in diagnostics

The integration of artificial intelligence (AI) and digital health technologies is transforming infectious disease diagnostics by improving speed, accuracy, and data-driven decision-making. AI-powered algorithms are increasingly used to analyze complex diagnostic data, detect patterns, and assist in faster interpretation of test results, thereby reducing human error and turnaround time. In addition, AI supports predictive analytics and outbreak forecasting, enabling healthcare systems to respond proactively to emerging infectious threats.

Market Drivers

Growing preference for the decentralized healthcare system and expansion of healthcare infrastructure in emerging markets drive market

POC diagnosis has become an essential component of patient-centric healthcare because of benefits like quick turnaround times and the ability to make treatment decisions immediately. Improvements in patient care have resulted from a preference shift from centralized to decentralized point-of-care testing for infectious diseases. The market is driven by the market participants' willingness to supply POC products to remote locations due to the rising demand for quick tests. Therefore, the adoption of rapid diagnostic testing in decentralized healthcare settings makes these devices easily accessible to personnel with less training and does away with the need for sample transportation to the core labs. 

The rapid development of healthcare infrastructure across emerging economies such as India, China, Brazil, and countries in Southeast Asia and Africa is a major driver for the infectious disease testing market. Governments and private players are increasingly investing in new hospitals, diagnostic laboratories, and public health centers, improving access to healthcare services. This expansion is particularly important in rural and semi-urban areas, where access to diagnostic facilities was previously limited, thereby significantly increasing the demand for infectious disease testing.

Market Restraints

Shortage of skilled professionals and weak supply chain restrain infectious disease testing market growth

The effective use of advanced diagnostic technologies requires highly skilled laboratory technicians, microbiologists, and trained healthcare professionals. However, many emerging economies face a significant shortage of such expertise, which hampers the efficient utilization of diagnostic infrastructure. Operating complex systems like PCR and NGS platforms involves specialized training in sample preparation, data analysis, and quality control, which is not always readily available. Additionally, inadequate training programs and limited access to continuous professional development further widen the skill gap. This leads to underutilization of diagnostic equipment, increased chances of errors, and delays in test results, ultimately affecting the quality of healthcare services.

Weak supply chain and logistics infrastructure create a significant restraint to the effective delivery of infectious disease testing services, particularly in emerging and remote regions. The timely availability of diagnostic kits, reagents, and laboratory equipment is critical for uninterrupted testing. However, inefficiencies in procurement, storage, and distribution often lead to stock shortages or delays. These disruptions can directly impact testing capacity and slow down disease detection efforts. Additionally, infectious disease diagnostics often require proper sample handling, cold chain maintenance, and rapid transportation to laboratories. In regions with inadequate transportation networks and storage facilities, maintaining these conditions becomes difficult, increasing the risk of sample degradation and inaccurate results. Such logistical constraints not only delay diagnosis and treatment but also hinder large-scale screening programs, ultimately limiting the overall growth of the infectious disease testing market.

Market Opportunities

Increasing demand for multiplex & syndromic testing panels and public-private partnerships (ppps) offer growth opportunities for infectious disease testing market players

Public-private partnerships are emerging as a key opportunity in the infectious disease testing market, as governments collaborate with private diagnostic companies, pharmaceutical firms, and technology providers to strengthen healthcare systems. These partnerships help in expanding diagnostic infrastructure, improving laboratory capacity, and ensuring efficient distribution of testing kits and equipment. By leveraging private sector innovation and public sector funding, PPPs enable faster deployment of advanced diagnostic technologies across both urban and rural regions.

The growing demand for multiplex and syndromic testing panels presents a significant opportunity for the market, as these solutions allow simultaneous detection of multiple pathogens from a single sample. This is particularly beneficial for diseases with similar symptoms, such as respiratory or gastrointestinal infections, where rapid and accurate differentiation is critical for effective treatment. Multiplex testing reduces the need for multiple individual tests, thereby saving time, lowering costs, and improving diagnostic efficiency. The increasing prevalence of co-infections and the need for comprehensive diagnostic approaches are driving the adoption of syndromic panels in hospitals and clinical laboratories.

Regional Insights

North America: market dominance through presence of major companies and early adoption of advanced technologies

North America dominated the market with the largest share of 36% in 2025 due to its rapid and early adoption of advanced diagnostic technologies. Healthcare providers and laboratories in the region are quick to integrate innovations such as Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), digital diagnostics, and AI-powered platforms into routine clinical practice. This early uptake is supported by strong investments in research and development, enabling faster commercialization and widespread availability of cutting-edge testing solutions. Regulatory support and a well-established innovation ecosystem allow quick approval and deployment of new diagnostic tools, especially during public health emergencies. For instance, during outbreaks, advanced molecular and rapid testing technologies are rapidly scaled across hospitals and laboratories, ensuring timely diagnosis and containment of infectious diseases.

The US holds a dominant position in the infectious disease testing market due to the strong presence of leading diagnostic companies who provide advanced diagnostic platforms, PCR systems, rapid test kits, and laboratory automation solutions widely used across hospitals, clinical laboratories, and research institutions. The CDC reported that the 2025–26 flu season caused ~11 million illnesses and 120,000 hospitalizations, with rising outpatient visits and increasing diagnostic testing needs. The US is heavily investing in real-time disease surveillance systems, which rely on continuous testing. Under the CDC’s Public Health Data Strategy, ~90% of emergency department visit data is now being captured for disease monitoring across most states.

The Canada infectious disease testing market is strongly supported by government-led surveillance and screening initiatives, primarily coordinated by the Public Health Agency of Canada, which monitors and tracks diseases through nationwide systems such as the Canadian Notifiable Disease Surveillance System (CNDSS). The government funds and implements large-scale screening programs for conditions like HIV, hepatitis, and tuberculosis, promoting early diagnosis and increasing testing volumes. Strengthened pandemic preparedness measures, including expanded laboratory capacity and rapid deployment of diagnostic tools, ensure timely response to outbreaks.

Asia Pacific: fastest growth driven by expanding healthcare infrastructure and significant investments in r&d innovations

The Asia Pacific region is expected to be the fastest-growing region in the market during the forecast period at a CAGR of 9.5%. The region is witnessing rapid expansion of healthcare infrastructure, which is a key factor driving growth in the infectious disease testing market. Governments across countries such as China, India, and Southeast Asian nations are making substantial investments in building new hospitals, upgrading diagnostic laboratories, and strengthening public health systems. These efforts aim to improve access to healthcare services, particularly in rural and underserved areas, thereby increasing the demand for infectious disease diagnostics. Large-scale government initiatives and funding programs are also enhancing laboratory networks, disease surveillance systems, and screening capabilities across the region. The expansion of private healthcare providers and diagnostic chains is further supporting the availability of advanced testing technologies, including PCR and rapid diagnostic kits.

China’s position as the most populous country in the region plays a crucial role in driving exceptionally high volumes of infectious disease testing. With a population exceeding 1.4 billion, there is a large and continuous demand for diagnostic services, including routine screenings, outbreak management, and preventive healthcare. The high population density, especially in urban areas, increases the risk of infectious disease transmission, thereby necessitating frequent and large-scale testing programs. The government actively conducts mass screening initiatives and nationwide surveillance programs to monitor and control diseases such as influenza, tuberculosis, and emerging viral infections, as seen in China through programs led by the Chinese Center for Disease Control and Prevention, including the National Notifiable Disease Reporting System (NNDRS) for real-time infectious disease tracking and large-scale tuberculosis screening and influenza surveillance networks implemented under the guidance of the National Health Commission of the People's Republic of China. The Chinese Center for Disease Control and Prevention conducted a nationwide sentinel surveillance in December 2025 to track respiratory infections across healthcare facilities. This results in substantial demand for diagnostic kits, reagents, and advanced testing technologies like PCR.

Japan plays a key role in the infectious disease testing market due to its strong emphasis on research and development (R&D) and continuous innovation. The country invests heavily in advancing diagnostic technologies, including molecular diagnostics (PCR), automation systems, and next-generation sequencing (NGS). Government support, along with collaboration between academic institutions and private companies, fosters the development of high-precision and reliable diagnostic solutions. The country’s focus on innovation has led to the introduction of advanced laboratory systems, rapid diagnostic tools, and high-throughput testing platforms, improving efficiency and accuracy in disease detection.

By Product & Service

The kits & reagents segment accounted for the largest share of 52% in 2025 due to the recurring nature of consumables, as every diagnostic test requires kits and reagents, unlike instruments, which are one-time purchases. Growth is driven by the rising volume of infectious disease testing, increasing adoption of molecular diagnostics (PCR, NGS), and continuous demand from hospitals, clinical laboratories, and point-of-care settings.

The software segment is expected to grow at a CAGR of 12% during the forecast period. This growth is driven by the increasing integration of AI, digital health platforms, and laboratory automation systems in diagnostics. Software solutions are essential for data management, real-time reporting, advanced analytics, and workflow optimization, especially with the rising complexity of molecular and high-throughput testing.

By Technology

The PCR (Polymerase Chain Reaction) segment accounted for the largest share of 45% in 2025. PCR remains the gold standard for infectious disease detection due to its high sensitivity, specificity, and rapid turnaround time. Growth is fueled by the increasing demand for accurate and early diagnosis, rising adoption of molecular diagnostics, and continuous advancements such as real-time and multiplex PCR technologies.

The DNA sequencing & NGS segment is projected to grow at a CAGR of 12% over the forecast period. This growth is driven by its ability to provide comprehensive pathogen profiling, detect novel and mutated strains, and support precision medicine and epidemiological surveillance. As healthcare systems move toward more data-driven and high-throughput diagnostics, NGS is emerging as a critical technology shaping the future of infectious disease testing.

By End User

The hospitals/clinical laboratories segment accounted for the largest share of 48% in 2025. These facilities are equipped with advanced diagnostic technologies such as PCR, immunoassays, and automated systems, enabling accurate and large-scale testing. Growth is supported by increasing hospital admissions, routine screening programs, and the need for rapid diagnosis in emergency and inpatient settings, making them the central hubs for infectious disease testing.

The reference laboratories segment is projected to grow at a CAGR of 10% over the forecast period. This growth is driven by the rising demand for specialized, high-throughput, and cost-effective testing services, particularly for complex and large-volume diagnostics. Reference labs offer advanced capabilities such as molecular diagnostics, NGS, and multiplex testing, often at lower costs due to economies of scale.